The survival rate of patients with pediatric cancer has increased considerably due to improved understanding of the biology of cancer subtypes, and the development of targeted therapies. This Review analyzes the recent findings that link pharmacogenomic variations with drug exposure, adverse effects, and efficacy of the emerging new treatments in pediatric oncology.
- Ching-Hon Pui
- Amar J. Gajjar
- Alberto S. Pappo
